Navigation Links
Phoenix conference highlights TGen's and Scottsdale Healthcare's contributions to molecular oncology
Date:1/9/2009

PHOENIX, Ariz. Jan. 8, 2009 Physician-scientists from the Translational Genomics Research Institute (TGen) and Scottsdale Healthcare will present their latest findings and techniques at a national conference designed to provide cancer doctors with new treatments for their patients.

"Molecular Oncology: The Sixth Vital Sign, What Every Oncologist Should Know" is intended to help cancer doctors provide better diagnosis, early detection as well as drugs and other treatments that in some cases can slow the growth or even shrink tumors.

"Given the explosion of new information on the genetic and cellular features of malignancy, the modern oncologist must master the significance and application of cancer-related sciences,'' said Dr. Ramesh K. Ramanathan, Medical Director of TGen Clinical Research Services at Scottsdale Healthcare, a partnership between TGen and Scottsdale Healthcare Corp.

Beyond the five vital signs of pulse, respiration, temperature, blood pressure and pain, is a new sixth vital sign molecular therapeutics. This is the ability to identify the causes of disease at the molecular level in order to provide the right drugs in the right amounts at the right times for the specific needs of individual patients; what is becoming better known in health circles as personalized medicine.

"This gap in knowledge and its application in clinical practice will be addressed in this conference,'' said Dr. Ramanathan, a Senior Investigator at TGen.

Dr. Ramanathan is the co-program director of the conference, along with Dr. Daniel Von Hoff, TGen's Physician-In-Chief and the Chief Scientific Officer at TCRS. Both doctors conduct groundbreaking personalized-medicine research and clinical drug trials at TCRS in Scottsdale, and both are on the clinical faculty of the University of Arizona College of Medicine. Both will present at the conference.

Other TGen and Scottsdale Healthcare scientists scheduled to present include: Dr. Jeffrey Trent, TGen's President and Scientific Director; Dr. Raoul Tibes, Director of the Hematological Malignancies Program at TCRS and an Associate Investigator at TGen; Dr. Stephen P. Anthony, Chief Medical Officer of TGen Drug Development Services (TD2) and a Senior Investigator at TGen; Dr. John Carpten, Director of TGen's Integrated Cancer Genomics Division and a Senior Investigator at TGen; and Gayle Jameson, M.S.N., Director of Supportive Care at TCRS and an Associate Investigator at TGen.

Besides oncologists, the target audience includes all physicians and health professionals involved in caring for cancer patients, and researchers interested in new cancer diagnostics and therapeutics.

Key objectives of the conference include:

  • Explaining the molecular and cellular features of malignancy in diagnostic and therapeutic approaches to the treatment of cancer, and identifying new diagnostic tools.

  • Assessing the effects and early clinical results of new, targeted drug therapies on solid tumors and malignant blood cancers.

  • Identifying new drug therapies that optimize treatment results and minimize side effects in specific biologic and clinical scenarios.

  • Evaluating clinical trials and translational methods of care and their proper use in clinical decision-making and patient management.


'/>"/>

Contact: Steve Yozwiak
syozwiak@tgen.org
602-343-8704
The Translational Genomics Research Institute
Source:Eurekalert

Related biology news :

1. Phoenix mission to Mars will search for climate clues
2. Atmel and Phoenix Technologies Collaborate to Create Next-generation Security Solutions for PCs
3. Phoenix Technologies and Atmel Collaborate to Create Next-Generation Security Solutions for PCs
4. Harmonizing Biobank Research Conference in 2009
5. PNNL researchers earn top honors at Supercomputing conference
6. Conference to explore sustainability of biofuels
7. Animal and biological science highlights: San Antonio Fluid Dynamics Conference, Nov. 23-25
8. Major conference on food Dec. 1-2, 2008
9. PNNL leadership in carbon sequestration featured at international conference
10. Engineer to present leak-proof method for carbon dioxide storage at international conference
11. Marine invasive species advance 50 km per decade, World Conference on Marine Biodiversity told
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2016)... Cercacor today introduced Ember TM Sport ... non-invasively measure hemoglobin, Oxygen Content, Oxygen Saturation, Perfusion ... in approximately 30 seconds. Smaller than a smartphone, using ... to key data about their bodies to help monitor ... Hemoglobin carries oxygen to muscles. When hemoglobin ...
(Date:11/19/2016)... 18, 2016 Securus Technologies, a leading provider ... safety, investigation, corrections and monitoring, announced today that it ... to have an independent technology judge determine who has ... high tech/sophisticated telephone calling platform, and the best customer ... do most of what we do – which clearly ...
(Date:11/15/2016)... , Nov. 15, 2016  Synthetic Biologics, ... developing therapeutics focused on the gut microbiome, today ... of 25,000,000 shares of its common stock and ... stock at a price to the public of ... to Synthetic Biologics from the offering, excluding the ...
Breaking Biology News(10 mins):
(Date:11/30/2016)... /PRNewswire/ -  Equicare Health Inc ., the leading supplier ... one of the top 100 companies in the 2016 ... distinguishes the top digital health companies across the globe. ... this year continually upgrading our product with the ongoing ... team," says Len Grenier , CEO of Equicare ...
(Date:11/30/2016)... , 30. November 2016   Merck ... heute die Unterzeichnung einer Reihe von Vereinbarungen ... wird Evotec AG Screeningleistungen für Mercks Palette ... Der Zugriff auf diese Bibliotheken in Kombination ... einen schnelleren Weg zur Ermittlung und Erforschung ...
(Date:11/30/2016)... ... November 30, 2016 , ... SSCI, the established leader ... the implications of the latest FDA guidance on pharmaceutical cocrystals as drug substance ... Cambridge, MA. , The event follows the successful November 15th event that ...
(Date:11/30/2016)... ... November 30, 2016 , ... On 28 November 2016, ... for four elements: nihonium (Nh), moscovium (Mc), tennessine (Ts), and oganesson (Og), respectively ... review, the names earlier proposed by the discoverers have been approved by the IUPAC ...
Breaking Biology Technology: